
QIAGEN N.V. QGEN
Geschäftsbericht 2024
hinzugefügt 28.02.2026
QIAGEN N.V. Betriebsaufwand 2011-2026 | QGEN
Betriebsaufwand Jährlich QIAGEN N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 821 M | 695 M | 692 M | 734 M | 769 M | 746 M | 651 M | 704 M | 752 M | 654 M | 650 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 821 M | 650 M | 715 M |
Betriebsaufwand anderer Aktien in der Diagnostik & Forschung
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
9.98 M | $ 2.89 | -2.36 % | $ 93.8 K | ||
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.99 B | $ 118.67 | 0.46 % | $ 36.1 B | ||
|
Celcuity
CELC
|
113 M | $ 109.39 | 1.0 % | $ 4.32 B | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 27.81 | -0.64 % | $ 772 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 177.9 | -0.41 % | $ 8.82 B | ||
|
Aspira Women's Health
AWH
|
37.1 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
181 M | $ 14.03 | -1.23 % | $ 424 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
106 M | $ 15.96 | 1.3 % | $ 2.07 B | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
41.3 M | $ 1.1 | -3.49 % | $ 1.4 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 208.55 | -0.82 % | $ 23.1 B | ||
|
Danaher Corporation
DHR
|
6.71 B | $ 202.93 | -1.44 % | $ 145 B | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | $ 103.39 | 0.04 % | $ 19.5 B | ||
|
Bioventus
BVS
|
217 M | $ 8.85 | 0.91 % | $ 554 M | ||
|
DarioHealth Corp.
DRIO
|
62.2 M | $ 10.5 | -2.33 % | $ 298 M | ||
|
DexCom
DXCM
|
1.89 B | $ 72.97 | -1.1 % | $ 28.5 B | ||
|
Burning Rock Biotech Limited
BNR
|
726 M | $ 24.2 | -3.82 % | $ 254 M | ||
|
CareDx, Inc
CDNA
|
411 M | $ 18.66 | -0.45 % | $ 994 M | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 108.73 | 0.42 % | $ 8.97 B | ||
|
IDEXX Laboratories
IDXX
|
1.3 B | $ 635.4 | -0.2 % | $ 51.1 B | ||
|
Illumina
ILMN
|
3.69 B | $ 130.82 | -1.55 % | $ 20.8 B | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
Guardant Health
GH
|
226 M | $ 93.48 | 1.35 % | $ 11.7 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 283.3 | -1.03 % | $ 23.6 B | ||
|
IQVIA Holdings
IQV
|
2.94 B | $ 174.31 | 0.02 % | $ 30 B | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 78.0 | 2.23 % | $ 5.26 B | ||
|
Brainsway Ltd.
BWAY
|
29.2 M | $ 23.0 | -2.91 % | $ 99.4 M | ||
|
Co-Diagnostics
CODX
|
45.3 M | - | - | $ 79.8 M | ||
|
Mettler-Toledo International
MTD
|
1.01 B | $ 1 317.07 | -0.45 % | $ 27.1 B | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
Myriad Genetics
MYGN
|
964 M | $ 5.26 | 4.99 % | $ 487 M | ||
|
NeoGenomics
NEO
|
430 M | $ 9.5 | - | $ 1.22 B | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
258 M | $ 208.69 | 4.26 % | $ 20.5 B | ||
|
Pacific Biosciences of California
PACB
|
600 M | $ 1.54 | -4.94 % | $ 462 M | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 11.01 | -1.3 % | $ 2.39 B | ||
|
Precipio
PRPO
|
13.6 M | $ 24.5 | -0.73 % | $ 31.8 M | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M |